{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T10:57:35Z","timestamp":1725793055155},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s12072-010-9238-7","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T14:43:09Z","timestamp":1293806589000},"page":"664-670","source":"Crossref","is-referenced-by-count":14,"title":["A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-na\u00efve patients with chronic hepatitis B"],"prefix":"10.1007","volume":"5","author":[{"given":"Su Rin","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Chul","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Mi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Hyoek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Cheol","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Woon","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"9238_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97\u2013107","journal-title":"J Viral Hepat"},{"key":"9238_CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227\u2013242","journal-title":"J Hepatol"},{"key":"9238_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350801300206","volume":"13","author":"C Niu","year":"2008","unstructured":"Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008;13:263\u2013269","journal-title":"Antivir Ther"},{"key":"9238_CR4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1517\/13543780802535760","volume":"17","author":"T Asselah","year":"2008","unstructured":"Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008;17:1963\u20131974","journal-title":"Expert Opin Investig Drugs"},{"key":"9238_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/AAC.40.2.380","volume":"40","author":"S Balakrishna Pai","year":"1996","unstructured":"Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel l-nucleoside, 2\u2032-fluoro-5-methyl-beta-l-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380\u2013386","journal-title":"Antimicrob Agents Chemother"},{"key":"9238_CR6","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.21629","volume":"45","author":"BC Yoo","year":"2007","unstructured":"Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172\u20131178","journal-title":"Hepatology"},{"key":"9238_CR7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/hep.21800","volume":"46","author":"BC Yoo","year":"2007","unstructured":"Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041\u20131048","journal-title":"Hepatology"},{"key":"9238_CR8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1073\/pnas.0307422100","volume":"101","author":"J Summers","year":"2004","unstructured":"Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101:638\u2013640","journal-title":"Proc Natl Acad Sci USA"},{"key":"9238_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","volume":"75","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311\u2013322","journal-title":"J Virol"},{"key":"9238_CR10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3346\/jkms.2010.25.5.738","volume":"25","author":"IH Kim","year":"2010","unstructured":"Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, et al. Treatment outcomes of clevudine versus lamivudine at week 48 in na\u00efve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci 2010;25:738\u2013745","journal-title":"J Korean Med Sci"},{"key":"9238_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/kjhep.2009.15.3.331","volume":"15","author":"MH Kim","year":"2009","unstructured":"Kim MH, Kim KA, Lee JS, Lee HW, Kim HJ, Yun SG, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331\u2013337","journal-title":"Korean J Hepatol"},{"key":"9238_CR12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350901400401","volume":"14","author":"SY Ko","year":"2009","unstructured":"Ko SY, Kwon SY, Choe WH, Kim BK, Kim KH, Lee CH. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1\u00a0year of an open-labelled prospective study. Antivir Ther 2009;14:585\u2013590","journal-title":"Antivir Ther"},{"key":"9238_CR13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1478-3231.2010.02245.x","volume":"30","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, et al. Comparison between clevudine and entecavir treatment for antiviral-na\u00efve patients with chronic hepatitis B. Liver Int 2010;30:834\u2013840","journal-title":"Liver Int"},{"key":"9238_CR14","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"J Dienstag","year":"2008","unstructured":"Dienstag J. Hepatitis B virus infection. N Engl J Med 2008;359:1486\u20131500","journal-title":"N Engl J Med"},{"key":"9238_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3350\/kjhep.2009.15.2.179","volume":"15","author":"HJ Lee","year":"2009","unstructured":"Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, et al. Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol 2009;15:179\u2013192","journal-title":"Korean J Hepatol"},{"key":"9238_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000264197","volume":"53","author":"JS Lee","year":"2010","unstructured":"Lee JS, Park ET, Kang SS, Gu ES, Kim JS, Jang DS, et al. Clevudine demonstrates potent antiviral activity in naive chronic hepatitis B patients. Intervirology 2010;53:83\u201386","journal-title":"Intervirology"},{"key":"9238_CR17","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1128\/JVI.02066-09","volume":"84","author":"SY Kwon","year":"2010","unstructured":"Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010;84:4494\u20134503","journal-title":"J Virol"},{"key":"9238_CR18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","volume":"44","author":"SK Fung","year":"2006","unstructured":"Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283\u2013290","journal-title":"J Hepatol"},{"key":"9238_CR19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","volume":"34","author":"MF Yuen","year":"2001","unstructured":"Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785\u2013791","journal-title":"Hepatology"},{"key":"9238_CR20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2893.2005.00712.x","volume":"13","author":"F Zoulim","year":"2006","unstructured":"Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278\u2013288","journal-title":"J Viral Hepat"},{"key":"9238_CR21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2009.04.019","volume":"51","author":"BK Kim","year":"2009","unstructured":"Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829\u2013834","journal-title":"J Hepatol"},{"key":"9238_CR22","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","volume":"49","author":"JI Seok","year":"2009","unstructured":"Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080\u20132086","journal-title":"Hepatology"},{"key":"9238_CR23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1872-034X.2009.00515.x","volume":"39","author":"WY Tak","year":"2009","unstructured":"Tak WY, Park SY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res 2009;39:944\u2013947","journal-title":"Hepatol Res"},{"key":"9238_CR24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jhep.2010.03.006","volume":"53","author":"WY Tak","year":"2010","unstructured":"Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261\u2013266","journal-title":"J Hepatol"},{"key":"9238_CR25","doi-asserted-by":"crossref","unstructured":"Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat 2010. doi: 10.1111\/j.1365-2893.2010.01304.x","DOI":"10.1111\/j.1365-2893.2010.01304.x"},{"key":"9238_CR26","doi-asserted-by":"crossref","unstructured":"Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, et al. Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2010. doi: 10.1111\/j.1365-2893.2010.01281.x","DOI":"10.1111\/j.1365-2893.2010.01281.x"},{"key":"9238_CR27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","volume":"51","author":"RD Fleischer","year":"2009","unstructured":"Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51:787\u2013791","journal-title":"J Hepatol"},{"key":"9238_CR28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486\u2013495","journal-title":"Gastroenterology"},{"issue":"1","key":"9238_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000122593","volume":"51","author":"JE Yeon","year":"2008","unstructured":"Yeon JE. Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology 2008;51(1):7\u201310","journal-title":"Intervirology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-010-9238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-010-9238-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-010-9238-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T17:48:42Z","timestamp":1685900922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-010-9238-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["9238"],"URL":"https:\/\/doi.org\/10.1007\/s12072-010-9238-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}